Weekly Grants Update
August 2, 2015
RFA-DK-15-030 - Type 1 Diabetes Pathfinder Award (DP2)
The Type 1 Diabetes Pathfinder Award (DP2) was first initiated in 2008 as part of the Strategic Plan for Type 1 Diabetes Research ( goal is to support a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research relevant to type 1 diabetes and its complications. The Type 1 Diabetes Pathfinder Award initiative complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The research proposed need not be in a conventional biomedical or behavioral discipline but must be relevant to type 1 diabetes. Letter of Intent is Due Jan. 17, 2016.
PA-15-317 - Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21)
This funding opportunity is intended to encourage pilot and feasibility clinical and laboratory based translational research relevant to the mission of the Division of Digestive Diseases and Nutrition, NIDDK without stringent requirements for preliminary data. Applications submitted to this FOA should propose research studies that will facilitate the translation of promising and relevant new developments into the clinical setting or that will advance our understanding of pathophysiological mechanism that may become the basis for diagnostic or therapeutic development. The emphasis is thus, on the development of small, randomized clinical trials; and on laboratory based translational feasibility studies that involve human subjectsbiospecimens relevant to diseases within the research mission of the Division of Digestive Diseases and Nutrition, NIDDK. Translational pilot and feasibility projects should involve human subjects research. The following studies will not be supported by this FOA: those that focus on obesity (please refer to the Office of Extramural Research Grants and Funding to search for multiple obesity related Funding Opportunity Announcements at and translational studies that utilize animal models. Application Due Date is Oct. 16, 2015.
Janssen Pharmaceuticals – Charitable Contributions
Janssen Pharmaceuticals has a charitable giving program focused on programs and services aimed at advancing recovery and healing for individuals and their families impacted by cardiovascular diseases and type II diabetes. Applications are Accepted on a Rolling Basis.